Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Kidney Biopsy Market Size

ID: MRFR/MED/3867-HCR
110 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Kidney Biopsy Market Research Report Information By End-User (Hospitals & Clinics, Urology Centers, Tertiary Care Centers and Others), By Indication (Kidney Failure, Kidney Transplant, Hematuria and Proteinuria), By Type (Percutaneous Biopsy and Surgical Biopsy), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Kidney Biopsy Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Kidney Biopsy Size

Kidney Biopsy Market Growth Projections and Opportunities

Rising kidney disease rates worldwide affect the Kidney Biopsy Market. As chronic kidney disease (CKD) and glomerulonephritis become more common, kidney biopsies are used more for diagnosis, boosting market expansion. Imaging technologies like ultrasound and CT keep the Kidney Biopsy Market active. Imaging improves kidney biopsy needle insertion, improving accuracy and safety. A focus on precision medicine and individualized renal disease therapy changes the market. Kidney biopsies provide tissue samples for molecular and genetic analysis, allowing more focused and effective treatments. Healthcare professionals and patients' knowledge and education regarding kidney biopsies' diagnostic value affects market growth. Educational activities increase biopsy referrals and patient acceptability, increasing market demand. High rates of diabetes and hypertension, which cause kidney disorders, affect market dynamics. These disorders raise the likelihood of renal problems, requiring kidney biopsies for appropriate diagnosis and therapy.

The market is affected by the worldwide demographic change toward aging. Kidney biopsies are needed for accurate diagnosis and treatment in older people, driving market demand. Percutaneous kidney biopsy and other less invasive biopsy methods keep the market active. Kidney biopsies are preferred by patients and doctors because to their lower problems and shorter recovery periods. AI in pathology analysis affects the Kidney Biopsy Market. AI applications speed up diagnostics and improve kidney biopsies' utility in patient care by enhancing pathology findings. Market growth is affected by nephrologists' kidney biopsy training. Nephrologists' knowledge increases biopsy use and improves kidney disease diagnosis and therapy. Kidney biopsies depend on regional healthcare infrastructure quality and accessibility. The kidney biopsy market is stronger in well-developed healthcare systems due to greater biopsy rates. Kidney biopsy reimbursement and insurance coverage affect patient access. Comprehensive biopsy reimbursement mechanisms ensure patient and healthcare provider financial viability, boosting market development. Regulatory clearances for innovative biopsy methods and technologies effect market access and uptake. Renal biopsies are safe and effective because to strict regulations, gaining confidence from doctors and patients.

Kidney Biopsy Market Size Graph
Author
Author Profile
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

FAQs

What is the projected market valuation of the Kidney Biopsy Market by 2035?

<p>The Kidney Biopsy Market is projected to reach approximately 3.777 USD Billion by 2035.</p>

What was the market valuation of the Kidney Biopsy Market in 2024?

<p>In 2024, the Kidney Biopsy Market was valued at 2.31 USD Billion.</p>

What is the expected CAGR for the Kidney Biopsy Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Kidney Biopsy Market during the forecast period 2025 - 2035 is 4.57%.</p>

Which segments are included in the End-User category of the Kidney Biopsy Market?

<p>The End-User category includes Hospitals & Clinics, Urology Centers, Tertiary Care Centers, and Others.</p>

What are the projected valuations for the Urology Centers segment by 2035?

<p>The Urology Centers segment is projected to grow from 0.46 USD Billion in 2024 to 0.75 USD Billion by 2035.</p>

Which key players are leading the Kidney Biopsy Market?

<p>Key players in the Kidney Biopsy Market include Fresenius Medical Care, Baxter International, and Thermo Fisher Scientific.</p>

What indications are covered in the Kidney Biopsy Market?

The indications include Kidney Failure, Kidney Transplant, Hematuria, and Proteinuria.

What is the projected growth for the Surgical Biopsy segment by 2035?

The Surgical Biopsy segment is expected to grow from 1.16 USD Billion in 2024 to 1.93 USD Billion by 2035.

How does the market valuation for Kidney Failure compare to other indications?

The market valuation for Kidney Failure is projected to increase from 0.693 USD Billion in 2024 to 0.99 USD Billion by 2035, indicating robust growth.

What is the significance of the projected growth in the Kidney Biopsy Market?

The projected growth in the Kidney Biopsy Market suggests an increasing demand for diagnostic procedures and advancements in kidney health management.

Market Summary

As per Market Research Future analysis, the Kidney Biopsy Market Size was estimated at 2.31 USD Billion in 2024. The Kidney Biopsy industry is projected to grow from 2.416 USD Billion in 2025 to 3.777 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 4.57% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Kidney Biopsy Market is experiencing significant growth driven by technological advancements and increasing awareness of kidney health.

  • Technological advancements are enhancing the precision and safety of kidney biopsy procedures. There is a notable shift towards minimally invasive procedures, particularly in North America, which is the largest market. Increased awareness of kidney health is driving demand in hospitals and clinics, the largest segment of the market. Rising incidence of kidney diseases and advancements in biopsy techniques are key drivers propelling growth in the Asia-Pacific region, the fastest-growing market.

Market Size & Forecast

2024 Market Size 2.31 (USD Billion)
2035 Market Size 3.777 (USD Billion)
CAGR (2025 - 2035) 4.57%
Largest Regional Market Share in 2024 North America

Major Players

Fresenius Medical Care (DE), Baxter International (US), Thermo Fisher Scientific (US), Abbott Laboratories (US), Siemens Healthineers (DE), Roche Diagnostics (CH), Philips Healthcare (NL), Medtronic (US), GE Healthcare (US)

Market Trends

The Kidney Biopsy Market is currently experiencing a notable evolution, driven by advancements in medical technology and an increasing prevalence of kidney-related diseases. As healthcare systems worldwide prioritize early diagnosis and personalized treatment, the demand for kidney biopsies is likely to rise. This procedure, which provides critical insights into kidney function and pathology, is becoming more refined, with innovations in imaging techniques and biopsy tools enhancing accuracy and patient safety. Furthermore, the growing awareness of chronic kidney disease among the population appears to be influencing the market positively, as more individuals seek diagnostic solutions to manage their health effectively. In addition, the Kidney Biopsy Market is witnessing a shift towards minimally invasive techniques, which may offer patients reduced recovery times and lower complication rates. The integration of advanced imaging modalities, such as ultrasound and CT guidance, is facilitating more precise needle placement, thereby improving the overall efficacy of the procedure. Moreover, the increasing collaboration between healthcare providers and technology firms suggests a future where kidney biopsy procedures are not only more efficient but also more accessible to a broader patient demographic. As the landscape continues to evolve, stakeholders in the Kidney Biopsy Market must remain vigilant to emerging trends and innovations that could shape the future of renal diagnostics.

Technological Advancements

The Kidney Biopsy Market is witnessing rapid technological advancements that enhance the precision and safety of procedures. Innovations in imaging techniques, such as real-time ultrasound and CT guidance, are improving the accuracy of needle placement, thereby reducing complications and increasing diagnostic yield.

Shift Towards Minimally Invasive Procedures

There is a discernible trend towards minimally invasive kidney biopsy techniques, which are gaining traction due to their potential to reduce patient discomfort and recovery time. This shift is likely to make kidney biopsies more appealing to both patients and healthcare providers.

Increased Awareness of Kidney Health

Growing awareness regarding kidney health and chronic kidney disease is influencing the Kidney Biopsy Market positively. As more individuals recognize the importance of early diagnosis and management, the demand for kidney biopsies is expected to rise, reflecting a proactive approach to renal health.

Kidney Biopsy Market Market Drivers

Rising Healthcare Expenditure

The upward trend in healthcare expenditure is a significant factor influencing the Kidney Biopsy Market. As countries allocate more resources to healthcare, there is a corresponding increase in the availability of advanced diagnostic services, including kidney biopsies. This trend is particularly evident in regions where healthcare systems are evolving to meet the needs of aging populations and rising disease prevalence. Enhanced access to healthcare services is likely to result in a higher volume of kidney biopsies being performed, thereby driving market growth. The Kidney Biopsy Market is expected to thrive as healthcare investments continue to rise.

Advancements in Biopsy Techniques

Innovations in biopsy techniques are significantly influencing the Kidney Biopsy Market. The introduction of ultrasound-guided and CT-guided biopsy methods has enhanced the precision and safety of kidney biopsies. These advancements not only reduce complications but also improve diagnostic accuracy, making them more appealing to healthcare providers. As a result, the market is witnessing an increase in the adoption of these advanced techniques. Furthermore, the integration of robotic-assisted technologies is expected to further streamline the biopsy process, potentially increasing the volume of procedures performed. This evolution in biopsy methodologies is likely to drive growth in the Kidney Biopsy Market.

Rising Incidence of Kidney Diseases

The increasing prevalence of kidney diseases is a primary driver of the Kidney Biopsy Market. According to recent data, chronic kidney disease affects approximately 10% of the population worldwide, leading to a heightened demand for diagnostic procedures such as kidney biopsies. This trend is further exacerbated by the aging population, which is more susceptible to renal disorders. As healthcare providers seek to improve patient outcomes, the need for accurate diagnosis through kidney biopsies becomes paramount. The Kidney Biopsy Market is thus positioned to grow as more patients require these procedures for effective management of their conditions.

Increased Funding for Kidney Research

The Kidney Biopsy Market is also being propelled by increased funding for kidney research initiatives. Governments and private organizations are recognizing the importance of kidney health, leading to substantial investments in research and development. This funding supports the exploration of new diagnostic techniques and therapies, which in turn drives the demand for kidney biopsies. As research progresses, the insights gained are likely to refine biopsy procedures and improve patient care. Consequently, the Kidney Biopsy Market stands to gain from this influx of resources dedicated to advancing kidney health.

Growing Demand for Personalized Medicine

The shift towards personalized medicine is reshaping the Kidney Biopsy Market. As healthcare moves away from a one-size-fits-all approach, the need for precise diagnostic tools becomes increasingly critical. Kidney biopsies provide essential information regarding the specific pathology of kidney diseases, enabling tailored treatment plans for patients. This trend is supported by the rising emphasis on individualized patient care, which is expected to drive the demand for kidney biopsies. Moreover, the Kidney Biopsy Market is likely to benefit from collaborations between nephrologists and pathologists, enhancing the overall diagnostic process and treatment outcomes.

Market Segment Insights

By End-User: Hospitals & Clinics (Largest) vs. Urology Centers (Fastest-Growing)

<p>In the Kidney Biopsy Market, Hospitals & Clinics hold the largest share among all end-users due to their comprehensive healthcare services and advanced technologies. They are equipped with skilled professionals and state-of-the-art facilities that enhance patient care, making them a preferred option for kidney biopsy procedures. On the other hand, Urology Centers, while having a smaller market share, are rapidly gaining traction, reflecting a growing trend towards specialized healthcare facilities that focus on urinary and renal issues.</p>

<p>Hospitals & Clinics (Dominant) vs. Urology Centers (Emerging)</p>

<p>Hospitals & Clinics serve as the dominant players in the Kidney Biopsy Market with their diverse range of services, including outpatient and inpatient care. They benefit from established infrastructure, a steady patient inflow, and collaboration with nephrologists and urologists. Urology Centers, while emerging, focus specifically on urological conditions, offering targeted expertise and tailored services. Their rise is driven by the increasing prevalence of kidney-related disorders and the demand for specialized diagnostic approaches. These centers often provide advanced imaging techniques and minimally invasive biopsy options, positioning themselves as vital healthcare providers in this niche market.</p>

By Indication: Kidney Failure (Largest) vs. Kidney Transplant (Fastest-Growing)

<p>The Kidney Biopsy Market is primarily segmented into four key indications: Kidney Failure, Kidney Transplant, Hematuria, and Proteinuria. Among these, the Kidney Failure segment holds the largest market share due to the rising prevalence of chronic kidney diseases and the increasing number of patients requiring biopsies for diagnosis. Conversely, the Kidney Transplant segment, while currently smaller, is rapidly gaining traction as advancements in transplant techniques and post-operative care enhance patient outcomes, driving demand for biopsies in this area. Growth trends in the Kidney Biopsy Market are primarily influenced by the aging population, which leads to a higher incidence of kidney-related conditions. Additionally, increasing awareness about the importance of early diagnosis and advancements in biopsy techniques, including minimally invasive options, are propelling the market forward. The Hematuria and Proteinuria segments are also expected to grow due to the rising awareness and diagnostic capabilities, though they presently play a smaller role compared to Kidney Failure and Kidney Transplant.</p>

<p>Kidney Failure (Dominant) vs. Hematuria (Emerging)</p>

<p>The Kidney Failure segment is currently the dominant player in the Kidney Biopsy Market, primarily due to the significant rise in chronic kidney disease cases. This segment benefits from established protocols and a robust patient base, as biopsies are crucial for accurately diagnosing the extent of kidney damage. In contrast, Hematuria, characterized by the presence of blood in urine, is an emerging segment driven by growing awareness and advancements in diagnostic methods. Patients with hematuria require careful evaluation, which usually involves biopsy procedures to rule out malignancies. While Hematuria is gaining recognition and sees increasing demand, it still remains subordinate to the more established Kidney Failure segment, requiring further development to achieve a comparable market presence.</p>

By Type: Percutaneous Biopsy (Largest) vs. Surgical Biopsy (Fastest-Growing)

<p>The Kidney Biopsy Market exhibits a clear segmentation in the type of biopsy performed, with Percutaneous Biopsy holding the largest market share. This method is preferred due to its minimally invasive nature and effectiveness, appealing to a diverse patient demographic. Conversely, Surgical Biopsy, while currently smaller in market share, is rapidly gaining attention as a valuable option in specific clinical scenarios where precision is paramount.</p>

<p>Biopsy Type: Percutaneous (Dominant) vs. Surgical (Emerging)</p>

<p>Percutaneous Biopsy continues to dominate the Kidney Biopsy Market due to its convenience and lower risk profile. This technique allows for targeted tissue sampling with reduced patient recovery time and minimal incision. On the other hand, Surgical Biopsy, though less common, is emerging as a critical option, particularly in complex cases where visualization and extensive sampling might be required. Its growth is propelled by advancements in surgical technologies and the increasing need for accurate diagnostic information, making it a vital alternative in the clinical toolbox.</p>

Get more detailed insights about Kidney Biopsy Market Research Report– Forecast till 2035

Regional Insights

North America : Leading Market Innovators

North America is the largest market for kidney biopsy, accounting for approximately 45% of the global share. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of kidney diseases, and rising awareness about early diagnosis. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring the availability of innovative biopsy technologies and procedures. The United States leads the market, supported by key players such as Abbott Laboratories, Thermo Fisher Scientific, and Fresenius Medical Care. The competitive landscape is characterized by continuous innovation and strategic partnerships among these companies, enhancing their market presence. Canada also contributes significantly, focusing on improving healthcare access and patient outcomes in kidney disease management.

Europe : Emerging Regulatory Frameworks

Europe is witnessing significant growth in the kidney biopsy market, holding approximately 30% of the global share. The region benefits from stringent regulatory frameworks that ensure high-quality healthcare services. Countries like Germany and France are at the forefront, driven by increasing healthcare expenditure and a rising incidence of chronic kidney diseases. The European Medicines Agency (EMA) plays a crucial role in regulating new biopsy technologies, fostering innovation and safety in medical practices. Germany is the largest market in Europe, with a robust presence of key players such as Siemens Healthineers and Roche Diagnostics. The competitive landscape is marked by collaborations between healthcare providers and technology firms, enhancing the availability of advanced biopsy solutions. France and the UK also contribute significantly, focusing on improving patient care and diagnostic accuracy in kidney diseases.

Asia-Pacific : Rapidly Expanding Healthcare Sector

Asia-Pacific is emerging as a significant player in the kidney biopsy market, accounting for about 20% of the global share. The region's growth is fueled by increasing healthcare investments, rising awareness of kidney diseases, and a growing aging population. Countries like China and India are witnessing a surge in demand for advanced diagnostic procedures, supported by government initiatives aimed at improving healthcare access and quality. China leads the market in Asia-Pacific, with a strong presence of local and international players, including Medtronic and GE Healthcare. The competitive landscape is evolving, with a focus on technological advancements and partnerships to enhance service delivery. India is also making strides in the market, driven by increasing healthcare infrastructure and a growing emphasis on preventive healthcare measures.

Middle East and Africa : Emerging Healthcare Opportunities

The Middle East and Africa region is gradually developing its kidney biopsy market, holding approximately 5% of the global share. The growth is driven by increasing healthcare investments, rising prevalence of kidney diseases, and a focus on improving healthcare infrastructure. Countries like South Africa and the UAE are leading the way, with government initiatives aimed at enhancing healthcare access and quality for patients. South Africa is the largest market in the region, supported by key players such as Philips Healthcare and Baxter International. The competitive landscape is characterized by a mix of local and international companies striving to improve diagnostic capabilities. The UAE is also emerging as a significant market, focusing on advanced healthcare solutions and partnerships to enhance patient care in kidney disease management.

Key Players and Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the kidney biopsy market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, kidney biopsy industry must offer cost-effective items.Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  kidney biopsy industry to benefit clients and increase the market sector. In recent years, the kidney biopsy industry has offered some of the most significant advantages to market.Major players in the kidney biopsy market attempting to increase market demand by investing in research and development operations include Boston Scientific Corporation (U.S.), Cook Medical (U.S.), C R Bard, Inc. (U.S.), Devicor Medical Products Inc. (U.S.), Hologic Inc. (U.S.), Intact Medical Corporation (U.S.), Precision Biopsy, LLC (U.S.), Scion Medical Technologies LLC (U.S.), Integra LifeSciences Corporation (U.S.), Creganna (U.S.), Focal Therapeutics, Inc. (U.S.), CareFusion (U.S.), Argon Medical Devices, Inc. (U.S.) and others.With its headquarters in Plano, Texas, Argon Medical is a maker of speciality medical goods on a  scale. Vascular surgery, interventional cardiology, interventional radiology, and oncology all have a variety of medical equipment available from Argon. The Argon brand is known for top-of-the-line solutions that enhance patient outcomes through percutaneous, image-guided operations. Argon supports its international customers through a direct sales organisation and through enduring connections with OEMs, strategic partners, and medical device distributors by utilizing a well-established sales and marketing infrastructure.Over 1000 people work at Argon worldwide in manufacturing facilities in Athens, Texas, Wheeling, Illinois, Rochester, New York, and Portage, Wisconsin.Cook Medical Inc., a division of Cook Group Inc., is a manufacturer, distributor, and developer of medical devices for minimally invasive procedures. Catheters, grafts, stents, plugs, wire guides, needles, balloons, feeding tubes, and extractors are among the main items produced by the company. Among other specialties, it provides goods and services in anesthesiology, bariatrics, cardiothoracic, general, gynecologic oncology, gynecology, neurosurgery, colorectal, endovascular, peripheral cardiology, plastic surgery, traumatology, urogynecology, and urology.

Key Companies in the Kidney Biopsy Market include

Industry Developments

September 2021 Natera, Inc., a leader in cell-free DNA (cfDNA) testing, recently unveiled Prospera with Quantification, the only cfDNA test for kidney rejection that provides three values on each report total cfDNA, the percentage of donor-derived cfDNA, and the amount of donor-derived cfDNA (dd-cfDNA). Comparatively to using the dd-cfDNA fraction alone, it has been suggested that combining these three measures will increase sensitivity for determining transplant rejection.

May 2021 AVROBIO, Inc., a pioneer in the field of clinical-stage gene therapy, provided an update on its regulatory preparations for AVR-RD-01, the first investigational lentiviral gene therapy for Fabry disease. The change is in response to the most recent regulatory advancement for Fabry disease treatments in the US.

Future Outlook

Kidney Biopsy Market Future Outlook

The Kidney Biopsy Market is projected to grow at a 4.57% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of kidney diseases, and rising demand for minimally invasive procedures.

New opportunities lie in:

  • <p>Development of advanced imaging technologies for enhanced biopsy accuracy. Expansion of telemedicine platforms for remote biopsy consultations. Partnerships with diagnostic labs for integrated biopsy services.</p>

By 2035, the Kidney Biopsy Market is expected to achieve substantial growth, reflecting evolving healthcare needs.

Market Segmentation

Kidney Biopsy Market Type Outlook

  • Percutaneous Biopsy
  • Surgical Biopsy

Kidney Biopsy Market End-User Outlook

  • Hospitals & Clinics
  • Urology Centers
  • Tertiary Care Centers
  • Others

Kidney Biopsy Market Indication Outlook

  • Kidney Failure
  • Kidney Transplant
  • Hematuria
  • Proteinuria

Report Scope

MARKET SIZE 2024 2.31(USD Billion)
MARKET SIZE 2025 2.416(USD Billion)
MARKET SIZE 2035 3.777(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 4.57% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Fresenius Medical Care (DE), Baxter International (US), Thermo Fisher Scientific (US), Abbott Laboratories (US), Siemens Healthineers (DE), Roche Diagnostics (CH), Philips Healthcare (NL), Medtronic (US), GE Healthcare (US)
Segments Covered End-User, Indication, Type, Region
Key Market Opportunities Advancements in minimally invasive techniques enhance patient outcomes in the Kidney Biopsy Market.
Key Market Dynamics Technological advancements in biopsy techniques drive market growth and enhance diagnostic accuracy in kidney disease management.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation of the Kidney Biopsy Market by 2035?

<p>The Kidney Biopsy Market is projected to reach approximately 3.777 USD Billion by 2035.</p>

What was the market valuation of the Kidney Biopsy Market in 2024?

<p>In 2024, the Kidney Biopsy Market was valued at 2.31 USD Billion.</p>

What is the expected CAGR for the Kidney Biopsy Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Kidney Biopsy Market during the forecast period 2025 - 2035 is 4.57%.</p>

Which segments are included in the End-User category of the Kidney Biopsy Market?

<p>The End-User category includes Hospitals & Clinics, Urology Centers, Tertiary Care Centers, and Others.</p>

What are the projected valuations for the Urology Centers segment by 2035?

<p>The Urology Centers segment is projected to grow from 0.46 USD Billion in 2024 to 0.75 USD Billion by 2035.</p>

Which key players are leading the Kidney Biopsy Market?

<p>Key players in the Kidney Biopsy Market include Fresenius Medical Care, Baxter International, and Thermo Fisher Scientific.</p>

What indications are covered in the Kidney Biopsy Market?

The indications include Kidney Failure, Kidney Transplant, Hematuria, and Proteinuria.

What is the projected growth for the Surgical Biopsy segment by 2035?

The Surgical Biopsy segment is expected to grow from 1.16 USD Billion in 2024 to 1.93 USD Billion by 2035.

How does the market valuation for Kidney Failure compare to other indications?

The market valuation for Kidney Failure is projected to increase from 0.693 USD Billion in 2024 to 0.99 USD Billion by 2035, indicating robust growth.

What is the significance of the projected growth in the Kidney Biopsy Market?

The projected growth in the Kidney Biopsy Market suggests an increasing demand for diagnostic procedures and advancements in kidney health management.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY End-User (USD Billion)
    2. | | 4.1.1 Hospitals & Clinics
    3. | | 4.1.2 Urology Centers
    4. | | 4.1.3 Tertiary Care Centers
    5. | | 4.1.4 Others
    6. | 4.2 Healthcare, BY Indication (USD Billion)
    7. | | 4.2.1 Kidney Failure
    8. | | 4.2.2 Kidney Transplant
    9. | | 4.2.3 Hematuria
    10. | | 4.2.4 Proteinuria
    11. | 4.3 Healthcare, BY Type (USD Billion)
    12. | | 4.3.1 Percutaneous Biopsy
    13. | | 4.3.2 Surgical Biopsy
    14. | 4.4 Healthcare, BY Region (USD Billion)
    15. | | 4.4.1 North America
    16. | | | 4.4.1.1 US
    17. | | | 4.4.1.2 Canada
    18. | | 4.4.2 Europe
    19. | | | 4.4.2.1 Germany
    20. | | | 4.4.2.2 UK
    21. | | | 4.4.2.3 France
    22. | | | 4.4.2.4 Russia
    23. | | | 4.4.2.5 Italy
    24. | | | 4.4.2.6 Spain
    25. | | | 4.4.2.7 Rest of Europe
    26. | | 4.4.3 APAC
    27. | | | 4.4.3.1 China
    28. | | | 4.4.3.2 India
    29. | | | 4.4.3.3 Japan
    30. | | | 4.4.3.4 South Korea
    31. | | | 4.4.3.5 Malaysia
    32. | | | 4.4.3.6 Thailand
    33. | | | 4.4.3.7 Indonesia
    34. | | | 4.4.3.8 Rest of APAC
    35. | | 4.4.4 South America
    36. | | | 4.4.4.1 Brazil
    37. | | | 4.4.4.2 Mexico
    38. | | | 4.4.4.3 Argentina
    39. | | | 4.4.4.4 Rest of South America
    40. | | 4.4.5 MEA
    41. | | | 4.4.5.1 GCC Countries
    42. | | | 4.4.5.2 South Africa
    43. | | | 4.4.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Fresenius Medical Care (DE)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Baxter International (US)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Thermo Fisher Scientific (US)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Abbott Laboratories (US)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 Siemens Healthineers (DE)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Roche Diagnostics (CH)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Philips Healthcare (NL)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Medtronic (US)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 GE Healthcare (US)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY END-USER
    4. | 6.4 US MARKET ANALYSIS BY INDICATION
    5. | 6.5 US MARKET ANALYSIS BY TYPE
    6. | 6.6 CANADA MARKET ANALYSIS BY END-USER
    7. | 6.7 CANADA MARKET ANALYSIS BY INDICATION
    8. | 6.8 CANADA MARKET ANALYSIS BY TYPE
    9. | 6.9 EUROPE MARKET ANALYSIS
    10. | 6.10 GERMANY MARKET ANALYSIS BY END-USER
    11. | 6.11 GERMANY MARKET ANALYSIS BY INDICATION
    12. | 6.12 GERMANY MARKET ANALYSIS BY TYPE
    13. | 6.13 UK MARKET ANALYSIS BY END-USER
    14. | 6.14 UK MARKET ANALYSIS BY INDICATION
    15. | 6.15 UK MARKET ANALYSIS BY TYPE
    16. | 6.16 FRANCE MARKET ANALYSIS BY END-USER
    17. | 6.17 FRANCE MARKET ANALYSIS BY INDICATION
    18. | 6.18 FRANCE MARKET ANALYSIS BY TYPE
    19. | 6.19 RUSSIA MARKET ANALYSIS BY END-USER
    20. | 6.20 RUSSIA MARKET ANALYSIS BY INDICATION
    21. | 6.21 RUSSIA MARKET ANALYSIS BY TYPE
    22. | 6.22 ITALY MARKET ANALYSIS BY END-USER
    23. | 6.23 ITALY MARKET ANALYSIS BY INDICATION
    24. | 6.24 ITALY MARKET ANALYSIS BY TYPE
    25. | 6.25 SPAIN MARKET ANALYSIS BY END-USER
    26. | 6.26 SPAIN MARKET ANALYSIS BY INDICATION
    27. | 6.27 SPAIN MARKET ANALYSIS BY TYPE
    28. | 6.28 REST OF EUROPE MARKET ANALYSIS BY END-USER
    29. | 6.29 REST OF EUROPE MARKET ANALYSIS BY INDICATION
    30. | 6.30 REST OF EUROPE MARKET ANALYSIS BY TYPE
    31. | 6.31 APAC MARKET ANALYSIS
    32. | 6.32 CHINA MARKET ANALYSIS BY END-USER
    33. | 6.33 CHINA MARKET ANALYSIS BY INDICATION
    34. | 6.34 CHINA MARKET ANALYSIS BY TYPE
    35. | 6.35 INDIA MARKET ANALYSIS BY END-USER
    36. | 6.36 INDIA MARKET ANALYSIS BY INDICATION
    37. | 6.37 INDIA MARKET ANALYSIS BY TYPE
    38. | 6.38 JAPAN MARKET ANALYSIS BY END-USER
    39. | 6.39 JAPAN MARKET ANALYSIS BY INDICATION
    40. | 6.40 JAPAN MARKET ANALYSIS BY TYPE
    41. | 6.41 SOUTH KOREA MARKET ANALYSIS BY END-USER
    42. | 6.42 SOUTH KOREA MARKET ANALYSIS BY INDICATION
    43. | 6.43 SOUTH KOREA MARKET ANALYSIS BY TYPE
    44. | 6.44 MALAYSIA MARKET ANALYSIS BY END-USER
    45. | 6.45 MALAYSIA MARKET ANALYSIS BY INDICATION
    46. | 6.46 MALAYSIA MARKET ANALYSIS BY TYPE
    47. | 6.47 THAILAND MARKET ANALYSIS BY END-USER
    48. | 6.48 THAILAND MARKET ANALYSIS BY INDICATION
    49. | 6.49 THAILAND MARKET ANALYSIS BY TYPE
    50. | 6.50 INDONESIA MARKET ANALYSIS BY END-USER
    51. | 6.51 INDONESIA MARKET ANALYSIS BY INDICATION
    52. | 6.52 INDONESIA MARKET ANALYSIS BY TYPE
    53. | 6.53 REST OF APAC MARKET ANALYSIS BY END-USER
    54. | 6.54 REST OF APAC MARKET ANALYSIS BY INDICATION
    55. | 6.55 REST OF APAC MARKET ANALYSIS BY TYPE
    56. | 6.56 SOUTH AMERICA MARKET ANALYSIS
    57. | 6.57 BRAZIL MARKET ANALYSIS BY END-USER
    58. | 6.58 BRAZIL MARKET ANALYSIS BY INDICATION
    59. | 6.59 BRAZIL MARKET ANALYSIS BY TYPE
    60. | 6.60 MEXICO MARKET ANALYSIS BY END-USER
    61. | 6.61 MEXICO MARKET ANALYSIS BY INDICATION
    62. | 6.62 MEXICO MARKET ANALYSIS BY TYPE
    63. | 6.63 ARGENTINA MARKET ANALYSIS BY END-USER
    64. | 6.64 ARGENTINA MARKET ANALYSIS BY INDICATION
    65. | 6.65 ARGENTINA MARKET ANALYSIS BY TYPE
    66. | 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER
    67. | 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
    68. | 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
    69. | 6.69 MEA MARKET ANALYSIS
    70. | 6.70 GCC COUNTRIES MARKET ANALYSIS BY END-USER
    71. | 6.71 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
    72. | 6.72 GCC COUNTRIES MARKET ANALYSIS BY TYPE
    73. | 6.73 SOUTH AFRICA MARKET ANALYSIS BY END-USER
    74. | 6.74 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
    75. | 6.75 SOUTH AFRICA MARKET ANALYSIS BY TYPE
    76. | 6.76 REST OF MEA MARKET ANALYSIS BY END-USER
    77. | 6.77 REST OF MEA MARKET ANALYSIS BY INDICATION
    78. | 6.78 REST OF MEA MARKET ANALYSIS BY TYPE
    79. | 6.79 KEY BUYING CRITERIA OF HEALTHCARE
    80. | 6.80 RESEARCH PROCESS OF MRFR
    81. | 6.81 DRO ANALYSIS OF HEALTHCARE
    82. | 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    83. | 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    84. | 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
    85. | 6.85 HEALTHCARE, BY END-USER, 2024 (% SHARE)
    86. | 6.86 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion)
    87. | 6.87 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
    88. | 6.88 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
    89. | 6.89 HEALTHCARE, BY TYPE, 2024 (% SHARE)
    90. | 6.90 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
    91. | 6.91 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY END-USER, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY INDICATION, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY TYPE, 2025-2035 (USD Billion)
    7. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    8. | | 7.3.1 BY END-USER, 2025-2035 (USD Billion)
    9. | | 7.3.2 BY INDICATION, 2025-2035 (USD Billion)
    10. | | 7.3.3 BY TYPE, 2025-2035 (USD Billion)
    11. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    12. | | 7.4.1 BY END-USER, 2025-2035 (USD Billion)
    13. | | 7.4.2 BY INDICATION, 2025-2035 (USD Billion)
    14. | | 7.4.3 BY TYPE, 2025-2035 (USD Billion)
    15. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    16. | | 7.5.1 BY END-USER, 2025-2035 (USD Billion)
    17. | | 7.5.2 BY INDICATION, 2025-2035 (USD Billion)
    18. | | 7.5.3 BY TYPE, 2025-2035 (USD Billion)
    19. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    20. | | 7.6.1 BY END-USER, 2025-2035 (USD Billion)
    21. | | 7.6.2 BY INDICATION, 2025-2035 (USD Billion)
    22. | | 7.6.3 BY TYPE, 2025-2035 (USD Billion)
    23. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.7.1 BY END-USER, 2025-2035 (USD Billion)
    25. | | 7.7.2 BY INDICATION, 2025-2035 (USD Billion)
    26. | | 7.7.3 BY TYPE, 2025-2035 (USD Billion)
    27. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    28. | | 7.8.1 BY END-USER, 2025-2035 (USD Billion)
    29. | | 7.8.2 BY INDICATION, 2025-2035 (USD Billion)
    30. | | 7.8.3 BY TYPE, 2025-2035 (USD Billion)
    31. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    32. | | 7.9.1 BY END-USER, 2025-2035 (USD Billion)
    33. | | 7.9.2 BY INDICATION, 2025-2035 (USD Billion)
    34. | | 7.9.3 BY TYPE, 2025-2035 (USD Billion)
    35. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    36. | | 7.10.1 BY END-USER, 2025-2035 (USD Billion)
    37. | | 7.10.2 BY INDICATION, 2025-2035 (USD Billion)
    38. | | 7.10.3 BY TYPE, 2025-2035 (USD Billion)
    39. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    40. | | 7.11.1 BY END-USER, 2025-2035 (USD Billion)
    41. | | 7.11.2 BY INDICATION, 2025-2035 (USD Billion)
    42. | | 7.11.3 BY TYPE, 2025-2035 (USD Billion)
    43. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.12.1 BY END-USER, 2025-2035 (USD Billion)
    45. | | 7.12.2 BY INDICATION, 2025-2035 (USD Billion)
    46. | | 7.12.3 BY TYPE, 2025-2035 (USD Billion)
    47. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    48. | | 7.13.1 BY END-USER, 2025-2035 (USD Billion)
    49. | | 7.13.2 BY INDICATION, 2025-2035 (USD Billion)
    50. | | 7.13.3 BY TYPE, 2025-2035 (USD Billion)
    51. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    52. | | 7.14.1 BY END-USER, 2025-2035 (USD Billion)
    53. | | 7.14.2 BY INDICATION, 2025-2035 (USD Billion)
    54. | | 7.14.3 BY TYPE, 2025-2035 (USD Billion)
    55. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    56. | | 7.15.1 BY END-USER, 2025-2035 (USD Billion)
    57. | | 7.15.2 BY INDICATION, 2025-2035 (USD Billion)
    58. | | 7.15.3 BY TYPE, 2025-2035 (USD Billion)
    59. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    60. | | 7.16.1 BY END-USER, 2025-2035 (USD Billion)
    61. | | 7.16.2 BY INDICATION, 2025-2035 (USD Billion)
    62. | | 7.16.3 BY TYPE, 2025-2035 (USD Billion)
    63. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.17.1 BY END-USER, 2025-2035 (USD Billion)
    65. | | 7.17.2 BY INDICATION, 2025-2035 (USD Billion)
    66. | | 7.17.3 BY TYPE, 2025-2035 (USD Billion)
    67. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    68. | | 7.18.1 BY END-USER, 2025-2035 (USD Billion)
    69. | | 7.18.2 BY INDICATION, 2025-2035 (USD Billion)
    70. | | 7.18.3 BY TYPE, 2025-2035 (USD Billion)
    71. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    72. | | 7.19.1 BY END-USER, 2025-2035 (USD Billion)
    73. | | 7.19.2 BY INDICATION, 2025-2035 (USD Billion)
    74. | | 7.19.3 BY TYPE, 2025-2035 (USD Billion)
    75. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    76. | | 7.20.1 BY END-USER, 2025-2035 (USD Billion)
    77. | | 7.20.2 BY INDICATION, 2025-2035 (USD Billion)
    78. | | 7.20.3 BY TYPE, 2025-2035 (USD Billion)
    79. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    80. | | 7.21.1 BY END-USER, 2025-2035 (USD Billion)
    81. | | 7.21.2 BY INDICATION, 2025-2035 (USD Billion)
    82. | | 7.21.3 BY TYPE, 2025-2035 (USD Billion)
    83. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.22.1 BY END-USER, 2025-2035 (USD Billion)
    85. | | 7.22.2 BY INDICATION, 2025-2035 (USD Billion)
    86. | | 7.22.3 BY TYPE, 2025-2035 (USD Billion)
    87. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    88. | | 7.23.1 BY END-USER, 2025-2035 (USD Billion)
    89. | | 7.23.2 BY INDICATION, 2025-2035 (USD Billion)
    90. | | 7.23.3 BY TYPE, 2025-2035 (USD Billion)
    91. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    92. | | 7.24.1 BY END-USER, 2025-2035 (USD Billion)
    93. | | 7.24.2 BY INDICATION, 2025-2035 (USD Billion)
    94. | | 7.24.3 BY TYPE, 2025-2035 (USD Billion)
    95. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    96. | | 7.25.1 BY END-USER, 2025-2035 (USD Billion)
    97. | | 7.25.2 BY INDICATION, 2025-2035 (USD Billion)
    98. | | 7.25.3 BY TYPE, 2025-2035 (USD Billion)
    99. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    100. | | 7.26.1 BY END-USER, 2025-2035 (USD Billion)
    101. | | 7.26.2 BY INDICATION, 2025-2035 (USD Billion)
    102. | | 7.26.3 BY TYPE, 2025-2035 (USD Billion)
    103. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.27.1 BY END-USER, 2025-2035 (USD Billion)
    105. | | 7.27.2 BY INDICATION, 2025-2035 (USD Billion)
    106. | | 7.27.3 BY TYPE, 2025-2035 (USD Billion)
    107. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    108. | | 7.28.1 BY END-USER, 2025-2035 (USD Billion)
    109. | | 7.28.2 BY INDICATION, 2025-2035 (USD Billion)
    110. | | 7.28.3 BY TYPE, 2025-2035 (USD Billion)
    111. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    112. | | 7.29.1 BY END-USER, 2025-2035 (USD Billion)
    113. | | 7.29.2 BY INDICATION, 2025-2035 (USD Billion)
    114. | | 7.29.3 BY TYPE, 2025-2035 (USD Billion)
    115. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    116. | | 7.30.1 BY END-USER, 2025-2035 (USD Billion)
    117. | | 7.30.2 BY INDICATION, 2025-2035 (USD Billion)
    118. | | 7.30.3 BY TYPE, 2025-2035 (USD Billion)
    119. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    120. | | 7.31.1
    121. | 7.32 ACQUISITION/PARTNERSHIP
    122. | | 7.32.1

Healthcare Market Segmentation

Healthcare By End-User (USD Billion, 2025-2035)

  • Hospitals & Clinics
  • Urology Centers
  • Tertiary Care Centers
  • Others

Healthcare By Indication (USD Billion, 2025-2035)

  • Kidney Failure
  • Kidney Transplant
  • Hematuria
  • Proteinuria

Healthcare By Type (USD Billion, 2025-2035)

  • Percutaneous Biopsy
  • Surgical Biopsy
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓